Skip to main content

Symptoms of anemia

  • Chapter

Abstract

Anemia is a frequent diagnosis in medicine. Anemia can be present as a disease by itself or can be the consequence of another disease. Anemia is particularly common in patients with cancer (Groopman and Itri 1999; Ludwig et al. 2004; Pirker et al. 2005). The incidence and severity of cancer—related anemia depend on cancer type, tumor stage, duration of the cancer, patient age, type as well as intensity of anticancer therapy, and on bone marrow reserve (Groopman and Itri 1999; Ludwig and Strasser 2001; Ludwig et al. 2004; Pirker et al. 2005). Cancer-related anemia can be caused by myelosuppressive chemotherapy and radiotherapy, tumor infiltration of the bone marrow, relative deficiency of erythropoietin, inappropriate response of the bone marrow, functional iron deficiency, nutritional deficiencies, bleeding, hemolysis, cytokines, anemia of chronic disease, and other factors (Cotran et al. 1999; Groopman and Itri 1999). The anemia of chronic disease is the most common type of non-treatment-induced anemia in patients with cancer (DeRienzo and Saleem 1990; Krantz 1994) and is caused by mainly an impaired marrow response to erythropoietin and partly also by a relative inadequacy of erythropoietin production (Dowlati 1997).

Keywords

  • Natl Cancer Inst
  • Darbepoetin Alfa
  • Erythropoietin Production
  • Bone Marrow Reserve
  • Immature Erythroid Cell

These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

This is a preview of subscription content, access via your institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • DOI: 10.1007/978-3-211-69459-6_12
  • Chapter length: 9 pages
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
eBook
USD   139.00
Price excludes VAT (USA)
  • ISBN: 978-3-211-69459-6
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Softcover Book
USD   179.00
Price excludes VAT (USA)

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Cotran RS, Kumar V, Collins T (1999) Red cell and bleeding disorders. In: Cotran RS, Kumar V, Collins T (eds.) Robbins pathologic basis of disease. WB Saunders Company, Philadelphia pp. 601–43

    Google Scholar 

  2. Bohlius J, Wilson J, Seidenfeld J, et al (2006) Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 98: 708–14

    CrossRef  CAS  PubMed  Google Scholar 

  3. Caro JJ, Salas M, Ward A, et al (2001) Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 91: 2214–21

    CrossRef  CAS  PubMed  Google Scholar 

  4. Cella D (1997) The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 34 [Suppl 2]: 13–9

    CAS  PubMed  Google Scholar 

  5. Cella D, Zagari MJ, Vandoros C, et al (2003) Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population. J Clin Oncol 21: 366–73

    CrossRef  PubMed  Google Scholar 

  6. Curt GA, Breitbart W, Cella D, et al (2000) Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist 5: 353–60

    CrossRef  CAS  PubMed  Google Scholar 

  7. DeRienzo DP, Saleem A (1990) Anemia of chronic disease: a review of pathogenesis. Tex Med 86: 80–3

    CAS  PubMed  Google Scholar 

  8. Dowlati A, R’Zik S, Fillet G, et al (1997) Anaemia of lung cancer is due to impaired erythroid marrow response to erythropoietin stimulation as well as relative inadequacy of erythropoietin production. Br J Haematol 97: 297–9

    CrossRef  CAS  PubMed  Google Scholar 

  9. Fisher JW (2003) Erythropoietin: physiology and pharmacology update. Exp Biol Med 228: 1–14

    CAS  Google Scholar 

  10. Groopman JE, Itri LM (1999) Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 91: 1616–34

    CrossRef  CAS  PubMed  Google Scholar 

  11. Krantz SB (1994) Pathogenesis and treatment of the anemia of chronic disease. Am J Med Sci 307: 353–9

    CrossRef  CAS  PubMed  Google Scholar 

  12. Ludwig H, Strasser K (2001) Symptomatology of anemia. Semin Oncol 28 [Suppl 8]: 7–14

    CrossRef  CAS  PubMed  Google Scholar 

  13. Ludwig H, Van Belle S, Barrett-Lee P, Birgegard G, Bokemeyer C, Gascon P, Kosmidis P, Krzakowski M, Nortier J, Olmi P, Schneider M, Schrijvers D (2004) The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 40: 2293–306

    CrossRef  PubMed  Google Scholar 

  14. Pirker R, Wiesenberger K, Minar W (2005) Cancer-related anemia: clinical relevance and treatment strategies. Am J Cancer 4: 233–45

    CrossRef  CAS  Google Scholar 

  15. Portenoy RK, Itri LM (1999) Cancer-related fatigue: guidelines for evaluation and management. Oncologist 4: 1–10

    CAS  PubMed  Google Scholar 

  16. Rizzo JD, Lichtin AE, Woolf SH, et al (2002) Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 20: 4083–107

    CrossRef  CAS  PubMed  Google Scholar 

  17. Seidenfeld J, Piper M, Flamm C, et al (2001) Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst 93: 1204–14

    CrossRef  CAS  PubMed  Google Scholar 

  18. Stone P, Richards M, A’Hern R, et al (2000) A study to investigate the prevalence, severity and correlates of fatigue among patients with cancer in comparison with a control group of volunteers without cancer. Ann Oncol 11: 561–7

    CrossRef  CAS  PubMed  Google Scholar 

  19. Vansteenkiste J, Pirker R, Massuti B, et al (2002) Double-blind, placebocontrolled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 94: 1211–20

    CAS  PubMed  Google Scholar 

  20. Vogelzang NJ, Breitbart W, Cella D, et al (1997) Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 34 [Suppl 2]: 4–12

    CAS  PubMed  Google Scholar 

  21. World Health Organization (1968) Nutritional anemias. Reports of a WHO scientific group. Geneva

    Google Scholar 

  22. Yellen SB, Cella DF, Webster K, et al (1997) Measuring fatigue and other anemiarelated symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 13: 63–74

    CrossRef  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Robert Pirker MD .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and Permissions

Copyright information

© 2008 Springer-Verlag/Wien

About this chapter

Cite this chapter

Pirker, R. (2008). Symptoms of anemia. In: Nowrousian, M.R. (eds) Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology. Springer, Vienna. https://doi.org/10.1007/978-3-211-69459-6_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-211-69459-6_12

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-25223-9

  • Online ISBN: 978-3-211-69459-6

  • eBook Packages: MedicineMedicine (R0)